Related Experiment Video
Updated: May 11, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to
Gwan Gyu Song1, Jae-Hoon Kim1, Young Ho Lee2
1Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Korea.
Introduction:
The purpose of this study was to examine whether the insertion (I) or deletion (D) of angiotensin-converting enzyme (ACE) polymorphism confers susceptibility to sarcoidosis.
Methods:
A meta-analysis on the associations between the ACE I/D polymorphism and sarcoidosis was conducted.
Results:
Seventeen comparison studies consisting of 1556 cases and 2381 controls were available for the meta-analysis. Meta-analysis revealed a significant association between the D allele and sarcoidosis (OR 1.206, 95% CI 1.049-1.386, p = 0.009). An ethnicity-specific meta-analysis of the DD+ID genotype showed an association with sarcoidosis in East Asians (OR 1.342, 95% CI 1.041-1.729, p = 0.023). An association was found between the DD genotype of the ACE I/D polymorphism and sarcoidosis (OR 1.251, 95% CI 1.070-1.463, p = 0.005). Furthermore, stratification by ethnicity indicated an association between the DD genotype and sarcoidosis in Europeans (OR = 1.215, 95% CI = 1.010-1.462, p = 0.039).
Conclusions:
Our meta-analysis demonstrates that the ACE I/D polymorphism is associated with susceptibility to sarcoidosis in European and East Asian populations.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets